Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
clinical characteristics of coexistent chronic myeloid leukemia and bcr abl1 negative myeloproliferative neoplasms a retrospective study
Original title: “Clinical Characteristics of Coexistent Chronic Myeloid Leukemia and BCR::ABL1 Negative Myeloproliferative Neoplasms: A Retrospective Study.”
fam3a inhibits plasma triglyceride levels via microvasculature involved enhancement of vldl triglyceride hydrolysis and lipid uptake
Original title: “FAM3A Inhibits Plasma Triglyceride Levels via Microvasculature-Involved Enhancement of VLDL-Triglyceride Hydrolysis and Lipid Uptake.”
The Food and Drug Administration ... therapies for rare diseases, looking at standards for individual conditions instead of a one-size-fits-all approach. The “Rare Disease Framework Initiative” will review existing policies, seek input from patients and experts and come up with a “fit-for-purpose framework” for drug development and regulation, the FDA said. Officials plan to look at everything from pre-clinical trial engagement ... The Food and Drug Administration on Wednesday said it plans to “reimagine” the way it regulates therapies for rare diseases, looking at standards for individual conditions instead of a one-size-fits-all approach. The “Rare Disease Framework Initiative” will review existing policies, seek input from patients and experts and come up with a “fit-for-purpose framework” for drug development and regulation, the FDA said. Officials plan to look at everything from pre-clinical trial engagement through post-marketing requirements, the agency said in a white paper. A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said. But rare disease development is even harder; there are fewer patients available for research and less knowledge about both the condition and potential biomarkers that can serve as endpoints for a trial. That has often left regulators in a quandary as they try to weigh the routine demand for clear evidence of safety and efficacy against the need for new treatments for devastating conditions. Some 30 million Americans live with a rare disease, according to the FDA. But as of last year, only about 5% of recognized rare conditions had an approved treatment.
Original title: “FDA ‘reset’ continues with new plan for reviewing rare disease drugs | Healthcare Dive”
The Food and Drug Administration ... therapies for rare diseases, looking at standards for individual conditions instead of a one-size-fits-all approach. The “Rare Disease Framework Initiative” will review existing policies, seek input from patients and experts and come up with a “fit-for-purpose framework” for drug development and regulation, the FDA said. Officials plan to look at everything from pre-clinical trial engagement ... The Food and Drug Administration on Wednesday said it plans to “reimagine” the way it regulates therapies for rare diseases, looking at standards for individual conditions instead of a one-size-fits-all approach. The “Rare Disease Framework Initiative” will review existing policies, seek input from patients and experts and come up with a “fit-for-purpose framework” for drug development and regulation, the FDA said. Officials plan to look at everything from pre-clinical trial engagement through post-marketing requirements, the agency said in a white paper. A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said. But rare disease development is even harder; there are fewer patients available for research and less knowledge about both the condition and potential biomarkers that can serve as endpoints for a trial. That has often left regulators in a quandary as they try to weigh the routine demand for clear evidence of safety and efficacy against the need for new treatments for devastating conditions. Some 30 million Americans live with a rare disease, according to the FDA. But as of last year, only about 5% of recognized rare conditions had an approved treatment.
Original title: “FDA ‘reset’ continues with new plan for reviewing rare disease drugs | Healthcare Dive”
The CLOVER-2 Phase 1b study is ... from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications, and the EMA has granted iopofosine I 131 PRIority ... The CLOVER-2 Phase 1b study is evaluating iopofosine I 131 in pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has granted iopofosine I 131 Breakthrough, six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications, and the EMA has granted iopofosine I 131 PRIority MEdicines (PRIME) designation. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the FDA and EMA regulatory pathways, ability to execute strategic alternatives, identify suitable collaborators, partners, licensees or purchasers for our product candidates and, if we are able to do so, to enter into binding agreements with regard to any of the foregoing, or to raise additional capital to support our operations, or our ability to fund our operations if we are unsuccessful with any of the foregoing. Because its targeted radiation works independently of the BTK pathway and other pathways currently targeted or attempting to be targeted, we believe it has the potential to remain effective as patients become refractory to today’s targeted therapies, and those still to come,” said Jarrod Longcor, chief operating officer of Cellectar Biosciences. “Patients in the immediate post-BTKi setting often face limited treatment options and increasingly refractory disease, making the robust response rates, durable clinical benefit, and favorable tolerability profile observed in this analysis especi The company is also preparing to submit a New Drug Application for accelerated approval with the U.S. Food and Drug Administration (FDA) in the first half of 2027, supported by the strength and maturity of the CLOVER WaM dataset.
Original title: “Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia”
In this episode of Denatured, presented by Cytiva, Jennifer Smith-Parker speaks to Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions at Cytiva. In this episode, we explore how biopharma’s real bottleneck isn’t too little data—it’s too little confidence in the decisions that drive development, manufacturing and commercialization.
Original title: “The decisions behind scientific progress”
Phase 2 development underway as DARE2 trial begins
Original title: “Lundbeck presents phase 1b data for Lu AF28996 in advanced Parkinson’s disease”
safety and efficacy of delpacibart zotadirsen in duchenne muscular dystrophy mutations amenable to exon 44 skipping in the usa explore44 a randomised placebo controlled double blind phase 1 2 trial
Original title: “Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial.”
pharmacological inhibition of rev erb ameliorates motor deficits in the 6 ohda lesioned mouse model of parkinson s disease
Original title: “Pharmacological inhibition of REV-ERBα ameliorates motor deficits in the 6-OHDA-lesioned mouse model of Parkinson's disease.”